FA Alpha Weekly Digest 10 08 2024

Wall Street’s stock picks can’t be trusted and the advertising bias of the mainstream financial media makes their news only sensationalist-driven. Gain an edge by knowing the trends that matter and some of the mispriced stocks in the market.

We bring you the FA Alpha Weekly Digest, a roundup of FA Alpha’s unique and unparalleled equity, credit, and macroeconomic insights over the past week.

In today’s digest, we’ll cover recent trends in consumer health, Global Payments (GPN), Skye Bioscience (SKYE), Capital One Financial (COF), and Neurocrine Biosciences (NBIX).

Post-pandemic spending might have doomed the economy

In the past month, U.S. consumers have amassed a record $1.14 trillion in credit card debt, fueled by rising interest rates and a surge in spending habits. Average credit card interest rates have also climbed to the highest in 30 years. With personal savings rates nearing pre-Great Recession levels and potential impacts from resuming student loan payments, consumer spending is expected to slow, signaling potential risks for the broader economy.

This payment solutions provider is transforming its business

Corporate transformations can significantly influence stock performance. For instance, Autodesk's shift to a subscription model could boost investor confidence since its recurring revenue. Conversely, Intel's attempt to enter the foundry business has faced market skepticism due to competition and transition challenges. Meanwhile, Global Payments (GPN) is undergoing a major transformation, streamlining operations, focusing on key areas, and divesting non-core assets. While these strategic moves aim for long-term growth, the market remains cautious due to risks tied to restructuring and execution. This uncertainty led to a 5.6% stock drop, but future success could shift investor sentiment positively.

Crossing the chasm with a weight-loss drug

Investing in biotech companies, especially pre-profit ones, is high risk due to the lengthy, expensive, and regulated drug development process, which includes multiple phases of trials. Skye Bioscience (SKYE) recently gained attention with its weight-loss drug, Nimacimab, which showed promising Phase 1 results without significant side effects, unlike some competing treatments. With the global weight-loss market projected to grow significantly, Skye's progress could position it for major gains if its drug proves successful in later trials.

This company shows improvement despite the decline in consumer health

Investors are growing concerned about U.S. consumer spending. Rising living costs and reduced savings lead to cutbacks in spending, negatively affecting sectors like consumer lending and payment processing. Despite financial pressures, consumers are not defaulting at alarming rates, which favors Capital One Financial. Lower delinquency rates reduce losses and limit the need for high provisions against bad loans, making the company an attractive option for investors. Still, monitoring consumer health remains crucial, as an economic downturn could pose challenges for Capital One.

This company helps people deal with the side effects of antidepressants

Neurocrine Biosciences (NBIX) has capitalized on the pandemic-driven demand for neurological drugs. Its leading product, Ingrezza, is expected to reach $2.3 billion in revenue this year. While the company has encountered difficulties with its schizophrenia drug trials, it maintains a promising pipeline with potential treatments for congenital adrenal hyperplasia (CAH) and cognitive impairments. Neurocrine's strategic focus on developing innovative therapies positions it favorably for future growth despite current challenges.

We hope you find this week’s FA Alpha Daily articles insightful.

See you next week as we talk about another set of interesting names.

To get access to FA Alpha’s best macro insights and top stock picks each month, click here.